These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 19896292)

  • 1. [Organ donation and risks of infections].
    Peigue-Lafeuille H
    Pathol Biol (Paris); 2011 Oct; 59(5):243-4. PubMed ID: 19896292
    [No Abstract]   [Full Text] [Related]  

  • 2. Deceased Organ Donors and PHS Risk Identification: Impact on Organ Usage and Outcomes.
    Pruett TL; Clark MA; Taranto SE
    Transplantation; 2017 Jul; 101(7):1670-1678. PubMed ID: 28252560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infections transmitted from donors to recipients following organ transplantation.
    Rao YG; Mirza DF
    Natl Med J India; 2005; 18(4):189-94. PubMed ID: 16252549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Informing candidates for solid-organ transplantation about donor risk factors.
    Halpern SD; Shaked A; Hasz RD; Caplan AL
    N Engl J Med; 2008 Jun; 358(26):2832-7. PubMed ID: 18579820
    [No Abstract]   [Full Text] [Related]  

  • 5. The "PHS Increased Risk" Label Is Associated With Nonutilization of Hundreds of Organs per Year.
    Volk ML; Wilk AR; Wolfe C; Kaul DR
    Transplantation; 2017 Jul; 101(7):1666-1669. PubMed ID: 28196048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probability of viremia with HBV, HCV, HIV, and HTLV among tissue donors in the United States.
    Zou S; Dodd RY; Stramer SL; Strong DM;
    N Engl J Med; 2004 Aug; 351(8):751-9. PubMed ID: 15317888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening recipients of increased risk donor organs: A multicenter retrospective study.
    Ison MG; Rana MM; Brizendine KD; Chimienti S; Le J; Kfoury R; Mohazabnia P; Theodoropoulos N
    Transpl Infect Dis; 2018 Jun; 20(3):e12862. PubMed ID: 29512233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantifying the risk of undetected HIV, hepatitis B virus, or hepatitis C virus infection in Public Health Service increased risk donors.
    Jones JM; Gurbaxani BM; Asher A; Sansom S; Annambhotla P; Moorman AC; Kamili S; Brooks JT; Basavaraju SV
    Am J Transplant; 2019 Sep; 19(9):2583-2593. PubMed ID: 30980600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Organ transplantation from "increased infectious risk donors": the experience of the Nord Italia Transplant program - A retrospective study.
    Grossi PA; Dalla Gasperina D; Lombardi D; Ricci A; Piccolo G; Nanni Costa A
    Transpl Int; 2018 Feb; 31(2):212-219. PubMed ID: 29057524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Provider response to a rare but highly publicized transmission of HIV through solid organ transplantation.
    Kucirka LM; Ros RL; Subramanian AK; Montgomery RA; Segev DL
    Arch Surg; 2011 Jan; 146(1):41-5. PubMed ID: 21242444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantation.
    Seem DL; Lee I; Umscheid CA; Kuehnert MJ;
    Public Health Rep; 2013 Jul; 128(4):247-343. PubMed ID: 23814319
    [No Abstract]   [Full Text] [Related]  

  • 12. Transmission of human immunodeficiency virus and hepatitis C virus through liver transplantation.
    Ahn J; Cohen SM
    Liver Transpl; 2008 Nov; 14(11):1603-8. PubMed ID: 18975294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Living-related, cadaveric, and living unrelated donor kidney transplants: a comparison study at King Fahad Hospital, Riyadh.
    Chaballout A; Said R; Alboghdadly S; Huraib S; Selim H
    Transplant Proc; 1995 Oct; 27(5):2775. PubMed ID: 7482910
    [No Abstract]   [Full Text] [Related]  

  • 14. Residual risk of transfusion-transmitted human immunodeficiency virus, hepatitis C virus, and hepatitis B virus infections in Italy.
    Gonzalez M; Règine V; Piccinini V; Vulcano F; Giampaolo A; Hassan HJ
    Transfusion; 2005 Oct; 45(10):1670-5. PubMed ID: 16181219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of medical and social history as prescreening to eliminate cornea donors at risk of having hepatitis B (HBV), hepatitis C (HCV), and human immunodeficiency virus (HIV).
    Davis AR
    Cornea; 1998 Jul; 17(4):457-8. PubMed ID: 9676925
    [No Abstract]   [Full Text] [Related]  

  • 16. [The possible risks of transmission of hematogenous viroses in a prison community].
    Liguori G; Rossano F; Perrella O; Iannucci F; Tempone G; Marinelli P
    Ann Ig; 1992; 4(5):289-92. PubMed ID: 1284901
    [No Abstract]   [Full Text] [Related]  

  • 17. Hepatitis C virus and organ transplantation.
    Miller J; Roth D; Schiff ER
    N Engl J Med; 1993 Feb; 328(7):512; author reply 513. PubMed ID: 8380623
    [No Abstract]   [Full Text] [Related]  

  • 18. Tissue allografts and health risks.
    Delloye C
    Acta Orthop Belg; 1994; 60 Suppl 1():62-7. PubMed ID: 7914392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of donor high-risk social behaviors on recipient survival in cardiac transplantation.
    Xu DS; Hartman D; Ludrosky K; Campbell J; Starling RC; Taylor DO; Smedira NG; Gonzalez-Stawinski GV
    Transplantation; 2010 Apr; 89(7):873-8. PubMed ID: 20090571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa.
    Vermeulen M; Lelie N; Sykes W; Crookes R; Swanevelder J; Gaggia L; Le Roux M; Kuun E; Gulube S; Reddy R
    Transfusion; 2009 Jun; 49(6):1115-25. PubMed ID: 19309474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.